Ernexa Therapeutics Inc. — Form 8-K
Filed November 19, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Ernexa amended its consulting agreement with CFO Mark J. Keeley effective November 9, 2026, adding $5,000 monthly cash compensation ($60,000 annualized) to his existing share-based pay. The original agreement dated August 10, 2026 provided CFO services at management's discretion. All other terms remain unchanged.
Why this rating
Annual cash outlay of $60K represents ~0.34% of company's $17.5M market cap—modest operating expense. Routine CFO compensation adjustment; no business operations, revenue, or equity structure affected.
See more from November 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.